The Form 4 filing, a report of insider stock trades, was filed on Nov. 17, 2026. It covers trades made one day earlier by Johanna Mercier, an officer at Gilead Sciences (GILD).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 3 |
| Shares Transacted | 28,000 |
| Price | $170.55 |
| Total Transaction Value | $4,775,527.47 |
| Insider | |
| Ticker Symbol | GILD |
| Company | GILEAD SCIENCES, INC. |
| Insider Name | Mercier Johanna |
| Insider Title | Chief Comm & Corp Aff Officer |
| Sector - Industry | Healthcare - Drug Manufacturers - General |
| Holdings | |
| Total Shares Owned After Transaction | 110,684 |
| Position Size Change | 20.19% |
| Filing | |
| Filing Date | 2026-11-17 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under transaction code S. The filing lists three transactions, all on Nov. 16, 2026, involving 28,000 shares in total.
What was the average price of the transaction?
The average sale price was $170.55 per share across the three transactions. Separate prices for each sale are not available in the transaction details.
How did this transaction affect the insider's holdings?
The sales reduced reported holdings by 28,000 shares, leaving 110,684 shares owned afterward. The shares sold were 20.19% of the 138,684 shares held before the sales.
What's the total transaction value?
The total value of the three sales was $4,775,527.47.
Are there any special circumstances around this transaction?
The transaction information includes a Rule 10b5-1 reference. These plans set trading instructions in advance. The reference may apply to the filing as a whole.
The filing's footnotes and plan details for each sale were not provided. It is therefore unclear which of the three sales the reference covers. The plan's adoption date, terms, and trading schedule are also unknown.
For research purposes only; not investment advice.